Genetic Association with Response to Intravitreal Ranibizumab in Patients with Neovascular AMD
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
PURPOSE: Neovascular age-related macular degeneration (AMD) resulting in decreased central vision severely impairs affected individuals. Current standard treatment is an intravitreal anti-VEGF therapy (ranibizumab), but responses to treatment show large variability. Genetic factors that influence AMD and that affect the outcome of ranibizumab treatment were sought within a sample of Swiss patients. METHODS: Changes in visual acuity (VA) after initiation of anti-VEGF treatment were observed during 12 months, and percentiles of VA were calculated. Genotypes of polymorphisms in known AMD susceptibility loci (CFH, CFB, HTRA1, AMRS2, and VEGFA) as well as not yet reported AMD-associated genes (KDR, LRP5, and FZD4) were determined, and their frequencies were compared. RESULTS: Of the 309 eyes included in the study, 243 completed VA assessment. On average, 3.9 ±2.6 ranibizumab injections were administered. Based on the change in visual acuity, two responder groups were established: 63 eyes were assigned to the poor responders (≤25th percentile) and 63 eyes to the good responders (≥75th percentile). Individuals with genotype CC of p.Y402H in CFH had a decreased chance of positive treatment outcome compared with those with the CT and TT genotypes (P = 0.005 and P = 0.006). In this study, the genotype combination of AG at CFH with CT at FZD4 (SNP rs10898563) promised an increased chance of positive treatment outcome (P = 0.004). Furthermore, the association with the known genetic susceptibility loci CFH, HTRA1, and AMRS2 were confirmed, and a risk-conferring polymorphism in one new locus, LRP5, was identified. CONCLUSIONS: Genetic predisposition may account for the variability in response to anti-VEGF treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Results from studies evaluating the ARMS2 A69S and HTRA1 promoter polymorphisms are also conflicting with regard to treatment response and no definitive conclusions can be drawn.9–11”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [11]
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Bootstrap Methods and Their Application
Loughin, T. M., Davison, A. C., & Hinkley, D. V. (1999) · Journal of the American Statistical Association · doi:10.2307/2669707 · Cited by 5,418
Models for Longitudinal Data: A Generalized Estimating Equation Approach
Zeger, S. L., Liang, K.-Y., & Albert, P. S. (1988) · Biometrics · doi:10.2307/2531734 · Cited by 4,505 · cited 1×
“Resampling was performed separately in patients with one or with two treated eyes and iterated 5000 times.(50,51)”
MethodComplement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Interaction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203
VEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122 · cited 1×
“One of the most important seems to be the production of vascular endothelial growth factor (VEGF).(1,2) Intravitreal injection of the anti-vascular endothelial growth factor (anti-VEGF) compounds, ranibizumab (Lucentis; Novartis, Basel, Switzerland; and Genentech Inc.”
BackgroundComplement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449
Complement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424
Cited by
Pennington, K. L., & DeAngelis, M. M. (2016) · Eye and Vision · doi:10.1186/s40662-016-0063-5 · Cited by 480
Risk factors and biomarkers of age-related macular degeneration
Lambert, N. G., ElShelmani, H., Singh, M. K., Mansergh, F. C., Wride, M. A., Padilla, M., Keegan, D., Hogg, R. E., & Ambati, B. K. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.04.003 · Cited by 351
“Patients with the CC Y402H genotype for CFH show significantly less improvements in visual acuity after anti-VEGF treatment than compared to CFH genotypes of TC and TT (Brantley et al., 2007; Kloeckener-Gruissem et al., 2011; Nischler et al., 2011; Teper et al., 2010).”
Clinical pharmacology of intravitreal anti-VEGF drugs
Fogli, S., Del Re, M., Rofi, E., Posarelli, C., Figus, M., & Danesi, R. (2018) · Eye · doi:10.1038/s41433-018-0021-7 · Cited by 224
Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration
Finger, R. P., Wickremasinghe, S. S., Baird, P. N., & Guymer, R. H. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2013.03.009 · Cited by 144
Hagstrom, S. A., Ying, G.-S., Pauer, G. J. T., Sturgill-Short, G. M., Huang, J., Callanan, D. G., Kim, I. K., Klein, M. L., Maguire, M. G., & Martin, D. F. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.11.037 · Cited by 142
Mechanism of Inflammation in Age-Related Macular Degeneration
Parmeggiani, F., Romano, M., Costagliola, C., Semeraro, F., Incorvaia, C., D’Angelo, S., Perri, P., Palma, P. D., Nadai, K. D., & Sebastiani, A. (2012) · Mediators of Inflammation · doi:10.1155/2012/546786 · Cited by 150
Kuroda, Y., Yamashiro, K., Miyake, M., Yoshikawa, M., Nakanishi, H., Oishi, A., Tamura, H., Ooto, S., Tsujikawa, A., & Yoshimura, N. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.06.053 · Cited by 124
“As for the CFH gene, 3 studies reported the association of polymorphisms to visual prognosis at 12 or 24 months after anti-VEGF treatment.(25,28,33) However, many studies denied the association of CFH gene polymorphisms with visual prognosis.”
BackgroundGorin, M. B. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.04.004 · Cited by 113
“Similarly a study of treatment response to intravitreal anti-VEGF therapy (ranibizumab) in a Swiss cohort (Kloeckener-Gruissem et al., 2011) also failed to find associations with VEGF polymorphisms though CFH and FZD4 alleles appeared to collectively impact the treatment outcome.”
BackgroundResultInfluentialSmailhodzic, D., Muether, P. S., Chen, J. L., Kwestro, A., Zhang, A. Y., Omar, A., van de Ven, J. P. H., KEUNEN, J. E. E., Kirchhof, B., Hoyng, C. B., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.05.040 · Cited by 123
The Neovascular Age-Related Macular Degeneration Database
Zarranz-Ventura, J., Liew, G., Johnston, R. L., Xing, W., Akerele, T., McKibbin, M., Downey, L., Natha, S., Chakravarthy, U., Bailey, C., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.04.026 · Cited by 103
Yamashiro, K., Tomita, K., Tsujikawa, A., Nakata, I., Akagi-Kurashige, Y., Miyake, M., Ooto, S., Tamura, H., & Yoshimura, N. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.01.010 · Cited by 90
Identifying Common Genetic Risk Factors of Diabetic Neuropathies
Witzel, I., Jelinek, H. F., Khalaf, K. A., Lee, S., Khandoker, A. H., & AlSafar, H. S. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00088 · Cited by 103
Abedi, F., Wickremasinghe, S., Richardson, A. J., Makalic, E., Schmidt, D. F., Sandhu, S. S., Baird, P. N., & Guymer, R. H. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.10.006 · Cited by 85
Polypoidal Choroidal Vasculopathy: Clinical Features and Genetic Predisposition
Honda, S., Matsumiya, W., & Negi, A. (2013) · Ophthalmologica · doi:10.1159/000355488 · Cited by 82
Towards the application of precision medicine in Age-Related Macular Degeneration
Cascella, R., Strafella, C., Caputo, V., Errichiello, V., Zampatti, S., Milano, F., Potenza, S., Mauriello, S., Novelli, G., Ricci, F., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.11.004 · Cited by 76
“Kloeckener-Gruissem et al. (2011) reported that the CC genotype is more prevalent among poor responders to Ranibizumab, compared to individuals carrying TT and TC genotypes.”
BackgroundAbedi, F., Wickremasinghe, S., Richardson, A. J., Islam, A. F. M., Guymer, R. H., & Baird, P. N. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.01.014 · Cited by 82
“This was reproduced in another study where patients with TT or TC genotypes at this SNP showed a better response to ranibizumab treatment compared with those with the homozygote risk CC genotype.(26) We have also previously reported that patients with apolipoprotein E (APOE) ε4 AMD protective allele showed a significa…”
ResultLotery, A. J., Gibson, J., Cree, A. J., Downes, S. M., Harding, S. P., Rogers, C. A., Reeves, B. C., Ennis, S., & Chakravarthy, U. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.07.046 · Cited by 64
“(%) Choroidal neovascularization 55 (50) 134 (59) 77 (67) 266 (59) Fluid 54 (44) 130 (52) 78 (64) 262 (53) Hemorrhage 17 (14) 44 (18) 18 (15) 79 (16) Other 10 (8) 32 (13) 24 (20) 66 (13) No choroidal neovascularization or unable to grade 5 (4) 5 (2) 3 (2) 13 (3)”
Hagstrom, S. A., Ying, G., Pauer, G. J. T., Sturgill-Short, G. M., Huang, J., Maguire, M. G., & Martín, D. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.109 · Cited by 72
Chen, H., Yu, K.-D., & Xu, G.-Z. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042464 · Cited by 51
“been reported, [9,10,11,12,13,14,15,16,17,18] though the results were inconclusive yet.”
Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD)
Otsuji, T., Sho, Tsumura, Koike, Tsuda, Nishimura, Takahashi, Y., & Nagaĭ (2013) · Clinical ophthalmology · doi:10.2147/opth.s46317 · Cited by 55
Complement System and Potential Therapeutics in Age-Related Macular Degeneration
Park, Y. G., Park, Y. S., & Kim, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136851 · Cited by 53
“However, evidence on the effect of CFB and C2 genetic variants on the response to AMD treatment is also still lacking [76].”
BackgroundHermann, M. M., van Asten, F., Muether, P. S., Smailhodzic, D., Lichtner, P., Hoyng, C. B., Kirchhof, B., Grefkes, C., den Hollander, A. I., & Fauser, S. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.047 · Cited by 51
Tian, J., Qin, X., Fang, K., Chen, Q., Hou, J., Li, J., Yu, W., Chen, D., Hu, Y., & Li, X. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.53 · Cited by 47
Kuroda, Y., Yamashiro, K., Tsujikawa, A., Ooto, S., Tamura, H., Oishi, A., Nakanishi, H., Miyake, M., Yoshikawa, M., & Yoshimura, N. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.09.032 · Cited by 45
Shah, A. R., Williams, S. L., Baumal, C. R., ROSNER, B. A., Duker, J. S., & Seddon, J. M. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.11.033 · Cited by 47
Baseline Predictors of Visual Acuity Outcome in Patients with Wet Age-Related Macular Degeneration
Zhang, X., & Lai, T. Y. Y. (2018) · BioMed Research International · doi:10.1155/2018/9640131 · Cited by 50
Menghini, M., Kloeckener‐Gruissem, B., Fleischhauer, J. C., Kurz-Levin, M. M., Sutter, F. K. P., Berger, W., & Barthelmes, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042014 · Cited by 44
Self-citationKeenan, T. D. L., Toso, M., Pappas, C. M., Nichols, L., Bishop, P. N., & Hageman, G. S. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-17009 · Cited by 43
Zhao, L., Grob, S., Avery, R. L., KIMURA, A. E., Pieramici, D. J., Lee, J., Rabena, M., Ortiz, S. O., Quach, J., Cao, G., et al. (2013) · Current Molecular Medicine · doi:10.2174/15665240113139990048 · Cited by 39
PHARMACOGENOMICS OF RESPONSE TO ANTI-VEGF THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION
Dedania, V. S., Grob, S., Zhang, K., & Bakri, S. J. (2015) · Retina · doi:10.1097/iae.0000000000000466 · Cited by 42
“Additionally, in two studies, some patients were not treatment naive.(13,20) This can complicate results as earlier studies have demonstrated that patients may show a greater response during the initial treatment phase.”
ResultBontzos, G., Bagheri, S., Ioannidi, L. D., Kim, I. K., Datseris, I., Gragoudas, E. S., Kabanarou, S. A., Miller, J. W., Tsilimbaris, M. K., & Vavvas, D. G. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.11.004 · Cited by 39
Predicting Non-response to Ranibizumab in Patients with Neovascular Age-related Macular Degeneration
van Asten, F., Rovers, M. M., Lechanteur, Y. T. E., Smailhodzic, D., Muether, P. S., Chen, J., den Hollander, A. I., Fauser, S., Hoyng, C. B., van der Wilt, G. J., et al. (2014) · Ophthalmic Epidemiology · doi:10.3109/09286586.2014.949010 · Cited by 37
El-Shazly, S., El-Bradey, M. H., & Tameesh, M. K. (2013) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12182 · Cited by 39
“The new field of pharmacogenetics aimed to enable ophthalmologists to individualize the treatment options based on the patient’s genetic profile for a disease; this will give a new attractive tool to choose the proper medication, to improve the response to therapy and to eliminate trial-and-error treatments.(18) The p…”
BackgroundResultHong, N., Shen, Y., Yu, C., Wang, S., & Tong, J. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13049 · Cited by 47
“A total of 76 related published studies were identified by an initial screen, and 29 papers were chosen after further examination (Brantley et al. 2007; Lee et al. 2009; Imai et al. 2010; Teper et al. 2010; Kloeckener-Gruissem et al. 2011; Nischler et al. 2011; Kang et al. 2012; McKibbin et al. 2012; Menghini et al. 2…”
BackgroundInfluentialFauser, S., & Lambrou, G. N. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2014.11.002 · Cited by 41
Boltz, A., Ruiß, M., Jonas, J. B., Tao, Y. K., Rensch, F., Weger, M., Garhöfer, G., Frantal, S., El‐Shabrawi, Y., & Schmetterer, L. F. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.001 · Cited by 40
Complement pathway biomarkers and age-related macular degeneration
Gemenetzi, M. K., & Lotery, A. J. (2015) · Eye · doi:10.1038/eye.2015.203 · Cited by 41
Park, U. C., Shin, J. Y., Kim, S. J., Shin, E., Lee, J. E., McCarthy, L. C., Newcombe, P. J., Xu, C., Chung, H., & Yu, H. G. (2013) · Retina · doi:10.1097/iae.0b013e3182979e1e · Cited by 40
“Patients homozygous for the CFH Y402H risk allele (CC genotype) were reported to have worse visual outcomes than CT or TT genotypes after ranibizumab or bevacizumab treatment in some studies.(13,18,36) In contrast, other studies reported no significant association between the CFH Y402H genotype and visual acuity chang…”
Hautamäki, A., Kivioja, J., Vavuli, S., Kakko, S., Savolainen, E.-R., Savolainen, M. J., Liinamaa, M. J., Seitsonen, S., Onkamo, P., Järvelä, I., et al. (2013) · Retina · doi:10.1097/iae.0b013e318285cf92 · Cited by 35
“In a study of ranibizumab treatment response, patients heterozygous for both polymorphisms CFH Y402H and frizzled homolog 4 (FZD4, rs10898563) seemed more likely to have a favorable outcome.(25) Poor visual acuity response with ranibizumab treatment has also been seen in homozygous carriers of S in LOC387715 A69S.”
BackgroundYamashiro, K., Mori, K., Honda, S., Kano, M., Yanagi, Y., Obana, A., Sakurada, Y., Sato, T., Nagai, Y., Hikichi, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09632-0 · Cited by 35
Pappas, C. M., Zouache, M. A., Matthews, S., Faust, C. D., Hageman, J. L., Williams, B. L., Richards, B. T., & Hageman, G. S. (2021) · Human Genomics · doi:10.1186/s40246-021-00359-8 · Cited by 38
Maugeri, A., Barchitta, M., Mazzone, M. G., Giuliano, F., & Agodi, A. (2018) · BioMed Research International · doi:10.1155/2018/7532507 · Cited by 36
“Lack of evidence exists about the effect of CFB and C2 genetic variants on response to intravitreal anti-VEGF injections; particularly, the rs641153 polymorphism did not show any pharmacogenetics effects in patients with neovascular AMD [104, 126].”
BackgroundCobos, E., Recalde, S., Anter, J., Hernandez‐Sanchez, M., Barreales, C., Olavarrieta, L., Valverde-Megías, A., Suarez‐Figueroa, M., Cruz, F., Abraldes, M. J., et al. (2017) · Acta Ophthalmologica · doi:10.1111/aos.13519 · Cited by 41
“studies have investigated the impact of genetic variants on anatomical and functional response to treatment in AMD patients (Brantley et al. 2007; Imai et al. 2010; Kloeckener-Gruissem et al. 2011; Boltz et al. 2012; Smailhodzic et al. 2012; Hagstrom et al. 2013; Kitchens et al. 2013).”
BackgroundResultInfluentialExploring the Use of Molecular Biomarkers for Precision Medicine in Age-Related Macular Degeneration
Lorés‐Motta, L., de Jong, E. K., & den Hollander, A. I. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0332-1 · Cited by 35
Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration
Danis, R. P., McLaughlin, M., Tolentino, M., Staurenghi, G., Ye, L., Xu, C., Kim, R. Y., Johnson, M. W., & for the Pazopanib Eye Drops Study Group (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303117 · Cited by 34
Chen, G., Tzekov, R., Li, W., Jiang, F., Mao, S., & Tong, Y. (2015) · Scientific Reports · doi:10.1038/srep14517 · Cited by 31
“…78.5 12 7 Hautamäki (2013) Prospective Finland Caucasian BVZ 96 78 3.5 7 Kitchens (2013) Retrospective United States Caucasian RBZ or BVZ 97 80 4 8 Kloeckener-Gruissem (2011) Retrospective Switzerland Caucasian RBZ 122 78.9 12 7 McKibbin (2012) Prospective United Kingdom Caucasian RBZ 104 81.5 6…”
BackgroundInfluentialVeritti, D., Sarao, V., Soppelsa, V., Danese, C., Chhablani, J. K., & Lanzetta, P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11020325 · Cited by 35
Park, U. C., Shin, J. Y., McCarthy, L. C., Kim, S. J., Park, J., Chung, H., & Yu, H. G. (2014) · PubMed Central · Cited by 37
Lazzeri, S., Figus, M., Orlandi, P., Fioravanti, A., Desidero, T. D., Agosta, E., Sartini, M. S., Posarelli, C., Nardi, M., Danesi, R., et al. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.43 · Cited by 32
Piermarocchi, S., Miotto, S., Colavito, D., Leon, A., & Segato, T. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12587 · Cited by 34
“Several studies found a poor response to intravitreal bevacizumab related to CFH risk alleles, with worse VA in homozygous patients compared to heterozygous and wild-type patients (Brantley et al. 2007; Kloeckener-Gruissem et al. 2011; Nischler et al. 2011).”
BackgroundCruz-González, F., Cabrillo-Estevez, L., López-Valverde, G., Cieza-Borrella, C., Hernández-Galilea, E., & González‐Sarmiento, R. (2014) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-014-2585-7 · Cited by 33
“Despite the results as genetic markers, different studies tried to find a relationship between the polymorphisms and the response to antiangiogenic treatment with also opposite results [13, 14, 23].”
ResultPharmacogenetics of Antiangiogenic and Antineovascular Therapies of Age-Related Macular Degeneration
Agosta, E., Lazzeri, S., Orlandi, P., Figus, M., Fioravanti, A., Desidero, T. D., Sartini, M. S., Nardi, M., Danesi, R., & Bocci, G. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.77 · Cited by 32
Dabir, S., Das, D., Jeyabalan, N., Mangalesh, S., Yadav, N., & Schouten, J. (2014) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.126186 · Cited by 27
“This strongly is suggesting the involvement of higher number of cell adhesion molecules in nonresponder group of patients.[22-24] We were unable to detect any diff erences in the expression levels of mRNA in Jak-Stat and MAPK pathway, although there are reports elucidating the role of Jak-Stat and MAPK pathway in diab…”
BackgroundHara, C., Wakabayashi, T., Toyama, H., Fukushima, Y., Sayanagi, K., Sato, S., Sakaguchi, H., & Nishida, K. (2018) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-312275 · Cited by 29
Biomarkers as Predictive Factors of Anti-VEGF Response
Bobadilla, M., Pariente, A., Ana, I., Peláez, R., Pérez-Sala, Á., & Larráyoz, I. M. (2022) · Biomedicines · doi:10.3390/biomedicines10051003 · Cited by 33
Hu, Z., Xie, P., Ding, Y., Yuan, D., & Liu, Q. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305488 · Cited by 26
Wang, V. M., Rosen, R. B., MEYERLE, C. B., Kurup, S. K., Ardeljan, D., Agrón, E., Tai, K. W., Pomykala, M., Chew, E. Y., Chan, C., et al. (2012) · PubMed Central · Cited by 32
Kuo, J. Z.-C., Wong, T. Y., & Ong, F. S.-C. (2013) · Expert Review of Ophthalmology · doi:10.1586/eop.13.3 · Cited by 28
Uchida, A., Hu, M., Babiuch, A. S., Srivastava, S. K., Singh, R. P., Kaiser, P. K., Talcott, K. E., Rachitskaya, A. V., & Ehlers, J. P. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218889 · Cited by 24
Dikmetaş, Ö., Kadayıfçılar, S., & Eldem, B. M. (2013) · Europe PMC (PubMed Central) · Cited by 28
Mohamad, N. A., Ramachandran, V., Isa, H. M., Chan, Y. M., Ngah, N. F., Ching, S. M., Hoo, F. K., Sulaiman, W. A. W., Mat, L. N. I., & Mohamed, M. H. (2019) · Human Genomics · doi:10.1186/s40246-019-0197-3 · Cited by 22
Lazzeri, S., Orlandi, P., Piaggi, P., Sartini, M. S., Casini, G., Guidi, G., Figus, M., Fioravanti, A., Desidero, T. D., Ripandelli, G., et al. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.153 · Cited by 21
Early middle age cholesterol levels and the association with age‐related macular degeneration
Kananen, F., Strandberg, T. E., Loukovaara, S., & Immonen, I. J. R. (2021) · Acta Ophthalmologica · doi:10.1111/aos.14774 · Cited by 31
“2011), LDL receptor related protein 5 (LRP5; Kloeckener-Gruissem et al. 2011), LRP6 and very low-density lipoprotein receptor (VLDLR; Haines et al.”
BackgroundZhou, Y., Chen, C., Wang, Y.-X., Tong, Y., Fang, X., Li, L., & Wang, Z. (2017) · BMC Ophthalmology · doi:10.1186/s12886-017-0487-2 · Cited by 23
“However, other study has not found any significant associations between HTRA1 and treatment outcomes among different genotypes [28].”
BackgroundFang, K., Tian, J., Qing, X., Li, S., Hou, J., Li, J., Yu, W., Chen, D., Hu, Y., & Li, X. (2013) · Journal of Ophthalmology · doi:10.1155/2013/676049 · Cited by 21
“did not find the association between the response to antiVEGF therapy (ranibizumab or bevacizumab) and the genotype in ARMS2 rs10490924 [20, 28–30], however; 2 other studies have reported thatHTRA1may influence the response to treatment of neovascular AMD with ranibizumab [31, 32].”
ResultVeloso, C. E. D. R., de Almeida, L. N. F., Recchia, F. M., Pelayes, D. E., & Nehemy, M. B. (2013) · Ophthalmic Research · doi:10.1159/000354328 · Cited by 22
Yıldız, B. K., Özdek, Ş., Ergün, M. A., Ergün, S. G., Tuncay, F. Y., & Elbeğ, Ş. (2016) · Ophthalmic Research · doi:10.1159/000446186 · Cited by 24
Corneal angiogenesis and lymphangiogenesis
Regenfu, B., Bock, F., & Cursiefen, C. (2012) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e328357b4a2 · Cited by 18
“Conventional cytotoxic drugs and antiangiogenic agents such as bevacizumab, an anti-VEGF humanized monoclonal antibody, have interindividual heterogeneity regarding their efficacy and toxicity in patients, which can lead to different treatment outcomes [44,45,48,49].”
BackgroundLorés‐Motta, L., van Asten, F., Muether, P. S., Smailhodzic, D., Groenewoud, J. M. M., Omar, A., Chen, J. L., Koenekoop, R. K., Fauser, S., Hoyng, C. B., et al. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000180 · Cited by 18
Matsumiya, W., Honda, S., Yanagisawa, S., Miki, A., Nagai, T., & Tsukahara, Y. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.51 · Cited by 19
Pharmacogenetics and Age-Related Macular Degeneration
Schwartz, S. G., & Brantley, M. A. (2011) · Journal of Ophthalmology · doi:10.1155/2011/252549 · Cited by 15
“Individual polymorphisms in the other genes were not significantly associated with treatment outcomes, but patients who were heterozygous at both CFH and FZD4 had significantly more favorable results; this genotype combination was identified in 36% of good responders versus 13% of poor responders [69].”
BackgroundInfluentialKozhevnikova, O. S., Фурсова, А. Ж., Derbeneva, A. S., Nikulich, I. F., Сергеевич, Т. М., Devyatkin, V. A., Rumyantseva, Y. V., Telegina, D. V., & Kolosova, N. G. (2022) · Biomedicines · doi:10.3390/biomedicines10071658 · Cited by 17
The challenge of predicting macular degeneration
Feigl, B., & Morris, C. P. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.603301 · Cited by 15
Medina, F. M. C., da Motta, A. A. L., Takahashi, W. Y., Carricondo, P. C., Motta, M. M. D. S., de Melo, M. B., & de Vasconcellos, J. P. C. (2015) · Ophthalmic Research · doi:10.1159/000439172 · Cited by 19
Yuan, D., Yuan, D., Liu, X., Yuan, S., Xie, P., & Liu, Q. (2013) · Ophthalmologica · doi:10.1159/000355068 · Cited by 18
Gorin, M. B., & daSilva, M. J. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.107894 · Cited by 14
Kanoff, J. M., & Miller, J. W. (2013) · Seminars in Ophthalmology · doi:10.3109/08820538.2013.825292 · Cited by 15
“Kloeckener-Gruissem et al.(35) ARMS2 Prospective study of 243 eyes receiving ranibizumab over 12 months.”
BackgroundInfluentialMcCarthy, L. C., Newcombe, P. J., Whittaker, J. C., Wurzelmann, J. I., Fries, M. A., Burnham, N. R., Cai, G., Stinnett, S. W., Trivedi, T., & Xu, C. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.03.021 · Cited by 15
Investigation of genetic base in the treatment of age-related macular degeneration
Gourgouli, K., Gourgouli, I., Tsaousis, G., Spai, S., Νισκοπούλου, Μ., Efthimiopoulos, S., & Lamnissou, K. (2020) · International Ophthalmology · doi:10.1007/s10792-019-01274-7 · Cited by 17
Kubicka‐Trząska, A., Żuber-Łaskawiec, K., Dziedzina, S., Sanak, M., Romanowska‐Dixon, B., & Karska‐Basta, I. (2022) · Medicina · doi:10.3390/medicina58050658 · Cited by 17
Medina, F. M. C., Motta, A. A. L. D., Takahashi, W. Y., Carricondo, P. C., Motta, M. M. D. S., Melo, M. B., & Vasconcellos, J. P. C. (2019) · Ophthalmic Research · doi:10.1159/000475995 · Cited by 12
Bakbak, B., Öztürk, B., Zamanı, A. G., Gönül, Ş., İyit, N., Gedik, Ş., & Yıldırım, M. S. (2015) · Current Eye Research · doi:10.3109/02713683.2015.1067325 · Cited by 13
“However, treatment of AMD with ranibizumab shows a broad spectrum of effects with regard to the course of VA, with some patients showing improvements in VA while others do not.(10) These results raise some question as to whether inherited pre-disposition (genetic variation) plays a role in treatment response.”
BackgroundZouache, M. A., Richards, B. T., Pappas, C. M., Anstadt, R. A., Liu, J., Corsetti, T., Matthews, S., Seager, N. A., Schmitz-Valckenberg, S., Fleckenstein, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44605-0 · Cited by 14
Veloso, C. E. D. R., de Almeida, L. N. F., & Nehemy, M. B. (2014) · Revista do Colégio Brasileiro de Cirurgiões · doi:10.1590/0100-69912014006002 · Cited by 15
Zeraati, H., Eslani, M., Mohammad, K., Peyman, G., Ramezani, A., Soheilian, M., & Yaseri, M. (2014) · Journal of Ophthalmic and Vision Research · doi:10.4103/2008-322x.150818 · Cited by 11
Switching Intravitreal anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration
Küçükerdönmez, C., Gelişken, F., Yoeruek, E., Bartz‐Schmidt, K. U., & Leitritz, M. A. (2014) · European Journal of Ophthalmology · doi:10.5301/ejo.5000480 · Cited by 10
“Moreover, recent studies showed an association between response to anti-VEGF treatment and genetic factors such as single nucleotide polymorphisms (18, 19).”
BackgroundBulğu, Y., Çetin, G. O., Caner, V., Çetin, E. N., Yaylalı, V., & Yıldırım, C. (2014) · Europe PMC (PubMed Central) · doi:10.3980/j.issn.2222-3959.2014.06 · Cited by 10
Arslan, J., & Baird, P. N. (2018) · Pharmacogenomics · doi:10.2217/pgs-2017-0183 · Cited by 7
GENETICS OF LARGE PIGMENT EPITHELIAL DETACHMENTS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Mouallem-Bézière, A., Blanco-Garavito, R., Richard, F., Mière, A., Jung, C., Rozet, J., & Souied, E. H. (2019) · Retina · doi:10.1097/iae.0000000000002454 · Cited by 8
HTRA1 rs11200638 variant and AMD risk from a comprehensive analysis about 15,316 subjects
Liu, Y., Jin, H., Wei, D., & Li, W. (2020) · BMC Medical Genetics · doi:10.1186/s12881-020-01047-5 · Cited by 7
Toward Personalized Medicine for Age-Related Macular Degeneration
Souied, E. H., & Leveziel, N. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.05.022 · Cited by 7
Brockmann, C., Brockmann, T., & Dawczynski, J. (2013) · Eye · doi:10.1038/eye.2013.159 · Cited by 6
Riveros, C., Vimieiro, R., Holliday, E. G., Oldmeadow, C. J., Wang, J. J., Mitchell, P., Attia, J., Scott, R. J., & Moscato, P. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-2155-3_12 · Cited by 5
Rodriguez, F. J., Ríos, H. A., Aguilar, M. C., Rosenstiehl, S. M., Gelvez, N. Y., López, G., & Tamayo, M. L. (2019) · Taiwan Journal of Ophthalmology · doi:10.4103/tjo.tjo_72_19 · Cited by 5
“The parameters were a risk of exposition 38%, risk of no exposition 11%,[6] exposed and no‐exposed reason 1, confidence interval 95%, power 80% and losses 10%, for a total of 61 study patients.”
BackgroundOczos, J., Grimm, C., Barthelmes, D., Sutter, F., Menghini, M., Kloeckener‐Gruissem, B., & Berger, W. (2012) · AGE · doi:10.1007/s11357-012-9467-x · Cited by 8
Self-citationGenetics in Age-Related Macular Degeneration: Current Research and Implications for Future Treatment
Broadhead, G., Chang, A., & McCluskey, P. (2012) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0b013e31826e1d4a · Cited by 4
Cheng, S. N., & Leng, T. (2016) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20160419-09 · Cited by 4
Mohamad, N. A., Ramachandran, V., Ismail, P., Isa, H. M., Chan, Y. M., Ngah, N. F., Bakri, N. M., Ching, S. M., Hoo, F. K., Sulaiman, W. A. W., et al. (2018) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2018.2493 · Cited by 7
“In the case of AMD, studies including larger samples of elderly patients and longer post-treatment follow-up periods reported more often that patients with the risk CFH Y402H C allele had a poorer response to treatment compared to the carriers of the low-risk T allele [11,18,19,27].”
BackgroundResultRoshanshad, A., Moosavi, S. A., & Arevalo, J. F. (2024) · Ophthalmic Research · doi:10.1159/000539377 · Cited by 6
Şengül, E. A., Artunay, Ö., Rasier, R., Koçkar, A., Afacan, C., Hançer, V. S., & Yüzbaşıoğlu, E. (2017) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2017.1311925 · Cited by 3
“Several studies have investigated the effects of genetic polymorphisms on response to treatment with intravitreal bevacizumab and ranibizumab administration; CFH Y402H CC polymorphism has been associated with poor response and TT polymorphism with a better response.(19) However, some other studies indicated that CFH Y…”
Result
Metadata
- Authors
- Kloeckener-Gruissem, B., Barthelmes, D., Labs, S., Schindler, C., Kurz-Levin, M., Michels, S., Fleischhauer, J., Berger, W., Sutter, F., & Menghini, M.
- Affiliations
- From the Institute of Medical Molecular Genetics, University of Zurich, Schwerzenbach, Switzerland; the 2Department of Biology, ETHZ (Eidgenössische Technische Hochschule Zürich), Zurich, Switzerland;
- The University of Sydney (AU)
- University of Zurich (CH)
- Swiss Tropical and Public Health Institute (CH)
- University Hospital Zurich (CH)
- Triemli Hospital (CH)
- Corresponding author
- Barthelmes, Daniel
- Labs, Stephan
- Schindler, Christian
- Kurz-Levin, Malaika
- Michels, Stephan
- Fleischhauer, Johannes
- Berger, Wolfgang
- Sutter, Florian
- Menghini, Moreno
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2011-06-30
- Volume
- 52
- Issue
- 7
- Pages
- 4694
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2018291910
- Cited by
- 120
- References
- 57
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 2 · 2022: 5 · 2021: 4 · 2020: 3 · 2019: 7 · 2018: 9 · 2017: 8 · 2016: 7 · 2015: 14 · 2014: 16 · 2013: 21 · 2012: 18
- FWCI
- 17.10
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- neovascular age-related macular degeneration, ranibizumab, anti-VEGF therapy, treatment response variability, genetic susceptibility, complement factor H, CFH Y402H polymorphism, FZD4, LRP5, HTRA1, VEGF-A, KDR, visual acuity, genetic association
- MeSH terms
- Ranibizumab, High-Temperature Requirement A Serine Peptidase 1, Aged, Aged, 80 and over, Antibodies, Monoclonal, DNA, Dose-Response Relationship, Drug, Female, Fluorescein Angiography, Follow-Up Studies, Fundus Oculi, Genotype, Humans, Macular Degeneration, Male, Polymorphism, Genetic, Complement Factor B, Proteins, Serine Endopeptidases, Time Factors, Visual Acuity, Retinal Neovascularization, Polymerase Chain Reaction, Complement Factor H, Genetic Predisposition to Disease, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.